Form 4: CervoMed Director Acquires Stock Options Following Board Election

Jeffrey V. Poulton, a director of CervoMed Inc., acquired stock options for 5,750 shares of common stock on June 14, 2024, following his election to the board.

Summary

• On June 14, 2024, Jeffrey V. Poulton, a director of CervoMed Inc. (CRVO), was granted an option to purchase 5,750 shares of the company's common stock.
• The grant was made in connection with Poulton's election to the Issuer's board of directors at its 2024 Annual Meeting of Stockholders.
• The options were granted under the Issuer's 2015 Equity Incentive Plan, as amended, in accordance with the terms of the Issuer's non-employee director compensation policy.
• The exercise price of the stock option is $19.01.
• The shares underlying the award will vest monthly over a one-year period, in equal installments, starting June 30, 2024, contingent upon continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and aligns director interests with shareholders. The vesting schedule encourages continued service.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The director's continued service is tied to the vesting of the stock options, incentivizing their ongoing contribution to the company.

Industry Context

Granting stock options to directors is a common practice to align their interests with shareholders and incentivize long-term value creation. The specific terms of the grant, such as the vesting schedule and exercise price, are typical for director compensation packages.

Comparison to Industry Standards

• Director compensation packages often include stock options or restricted stock units to align director interests with shareholder value.
• Vesting schedules for director equity awards typically range from one to three years, with monthly or quarterly vesting being common.
• The exercise price of $19.01 is relevant to the current market price of CervoMed's stock, which would determine the potential value of the options to the director.
• Comparing CervoMed's director compensation policy to those of similar-sized companies in the biotechnology sector would provide further context.

Stakeholder Impact

• Shareholders may view the granting of stock options positively as it aligns director interests with long-term value creation.
• The director is incentivized to contribute to the company's success to realize the value of the stock options.

Key Dates